✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Manogepix is an investigational drug.
There have been 4 clinical trials for Manogepix. The most recent clinical trial was a Phase 1 trial, which was initiated on September 15th 2019.
The most common disease conditions in clinical trials are Mycoses, Invasive Fungal Infections, and Infection. The leading clinical trial sponsors are Amplyx Pharmaceuticals, Pfizer, and [disabled in preview].
There is one US patent protecting this investigational drug and thirty-three international patents.
Recent Clinical Trials for Manogepix
|A Bioequivalence Study of APX001 High-load and Low-load Tablets||Pfizer||Phase 1|
|Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds||Amplyx Pharmaceuticals||Phase 2|
|A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001||Amplyx Pharmaceuticals||Phase 1|
Top disease conditions for Manogepix
Top clinical trial sponsors for Manogepix
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Manogepix||See Plans and Pricing||Heterocycle-substituted pyridine derivative's salt or crystal thereof||Eisai R&D Management Co., Ltd. (Tokyo, JP)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Manogepix||Australia||AU2008246798||2027-04-27||See Plans and Pricing|
|Manogepix||Canada||CA2685194||2027-04-27||See Plans and Pricing|
|Manogepix||China||CN101622251||2027-04-27||See Plans and Pricing|
|Manogepix||China||CN102702185||2027-04-27||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|